D
I-Mab IMAB
$3.42 -$0.06-1.72% NASDAQ
Recommendation
Prev Close
$3.48
Volume
1,420,899
Avg Vol (90D)
1,779,130
Market Cap
$400.62M
Dividend & Yield
--
52-Week Range
$0.595 - $5.90
P/E (TTM)
7.62
EPS (TTM)
$0.4567
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Retail investors among I-Mab's (NASDAQ:IMAB) largest stockholders and were hit after last week's 10% price drop
9/29/2025 - Simply Wall St
I-MAB (IMAB, $3.52) Stochastic Oscillator left the oversold zone on September 25, 2025
9/26/2025 - Tickeron - Technical Analysis
I-MAB (IMAB, $3.56) price exceeded its 50-day Moving Average on September 24, 2025
9/25/2025 - Tickeron - Stocks
15 Best Biotech Penny Stocks to Invest in Right Now
9/21/2025 - Insider Monkey
I-MAB (IMAB, $3.79) Aroon Indicator entered a Downtrend on September 19, 2025.
9/20/2025 - Tickeron - Stocks
I-Mab (NASDAQ:IMAB) Rating Lowered to "Hold" at Wall Street Zen
9/20/2025 - MarketBeat
I-MAB (IMAB, $3.65) Aroon Indicator entered a Downtrend on September 18, 2025.
9/19/2025 - Tickeron - Stocks
I-MAB (IMAB, $3.69) Aroon Indicator entered a Downtrend on September 17, 2025.
9/18/2025 - Tickeron - Stocks
I-MAB (IMAB, $3.72) Aroon Indicator entered a Downtrend on September 16, 2025.
9/17/2025 - Tickeron - Stocks
I-MAB (IMAB, $3.62) Aroon Indicator entered a Downtrend on September 15, 2025.
9/16/2025 - Tickeron - Stocks
I-Mab (NASDAQ:IMAB) Earns Buy Rating from Analysts at BTIG Research
9/11/2025 - MarketBeat
I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market
9/10/2025 - SeekingAlpha
I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market
9/10/2025 - Seeking Alpha - Long Ideas
BTIG Reiterates Buy Rating for IMAB with $7.00 Price Target IMAB Stock News
9/10/2025 - GuruFocus
I-Mab (IMAB) Stock Decline Seen as Overreaction by BTIG Analyst
9/10/2025 - GuruFocus
BTIG says buy I-Mab amid 'misperceived' China risk
9/10/2025 - TipRanks Financial Blog
BTIG says buy I-Mab amid 'misperceived' China risk
9/10/2025 - The Fly
Needham & Company LLC Reaffirms Buy Rating for I-Mab (NASDAQ:IMAB)
9/10/2025 - MarketBeat
I-MAB (IMAB, $4.6) Stochastic Oscillator left the oversold zone on September 09, 2025
9/10/2025 - Tickeron - Stocks
I-MAB (IMAB) Receives New "Buy" Rating from BTIG Analyst IMAB Stock News
9/9/2025 - GuruFocus
I-Mab initiated with a Buy at BTIG
9/9/2025 - TipRanks Financial Blog
I-Mab initiated with bullish view at BTIG, here's why
9/9/2025 - The Fly
I-MAB (IMAB, $4.27) Stochastic Oscillator left the oversold zone on September 08, 2025
9/9/2025 - Tickeron - Technical Analysis
Needham Reiterates Buy Rating for IMAB with $6.00 Price Target IMAB Stock News
9/8/2025 - GuruFocus
I-Mab to accelerate investment in givastomig
9/8/2025 - Seeking Alpha - Healthcare
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$212.68M
Total Debt (Q)
$3.88M
Total Liabilities (Q)
$11.52M
Book Value Per Share (Q)
$5.68
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, April 3, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
(est)
Price History
Loading...
Beta
1.20
7-Day Total Return
-6.30%
30-Day Total Return
-29.77%
60-Day Total Return
59.07%
90-Day Total Return
274.34%
Year to Date Total Return
277.48%
1-Year Total Return
197.39%
2-Year Total Return
178.05%
3-Year Total Return
-25.81%
5-Year Total Return
-91.23%
52-week Low
Apr 04, 2025 - $0.595
52-week High
Aug 15, 2025 - $5.90
Valuation
Market Cap
$400.62M - Small Cap
Enterprise Value
$238.48M
Price/Sales (TTM)
--
Price/Book (Q)
0.61
Dividends and Shares
Shares Outstanding
35.44
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.i-mabbiopharma.com
Phone Number
240 745 6330
Address
2440 Research Boulevard
Rockville, MD 20850
Country
United States
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which... more
NASDAQ 09/29/2025 4:00PM Eastern Quotes delayed